Inclisiran在纯合子家族性高胆固醇血症患者中的疗效、安全性与耐受性:ORION-5随机临床试验结果
ORION-5为3期、两部分、多中心研究,纳入56例纯合子家族性高胆固醇血症患者,随机2:1接受inclisiran 300 mg钠(相当于284 mg inclisiran)或安慰剂。主要终点为基线至第150天LDL-C百分比变化,安慰剂校正后为-1.68%(95%CI -29.19%至25.83%;P=0.90),无统计学显著性;PCSK9水平安慰剂校正后降低60.6%(P<0.0001)。
要点
- Inclisiran未显著降低纯合子家族性高胆固醇血症患者的LDL-C水平。
- Inclisiran显著降低PCSK9水平达60.6%,证实其靶点作用。
- Inclisiran安全性与耐受性良好,不良事件与安慰剂组无差异。
核心结论
- Inclisiran虽显著降低PCSK9水平,但未降低纯合子家族性高胆固醇血症患者的LDL-C水平。
- Inclisiran耐受性良好,安全性结果与既往研究一致。
研究设计与样本
- ORION-5为3期、两部分、多中心研究,纳入56例纯合子家族性高胆固醇血症患者。
- 第一部分为双盲6个月,患者按2:1随机接受inclisiran 300 mg钠(相当于284 mg inclisiran)或安慰剂。
- 第二部分为开放标签18个月,第一部分安慰剂组患者转换为inclisiran治疗。
主要发现
- 患者平均年龄42.7岁,女性占60.7%。
- inclisiran组和安慰剂组基线平均LDL-C分别为294.0 mg/dL和356.7 mg/dL。
- 基线至第150天LDL-C安慰剂校正百分比变化为-1.68%(95%CI -29.19%至25.83%;P=0.90),组间无统计学显著差异。
- 基线至第150天PCSK9安慰剂校正百分比变化为-60.6%(P<0.0001),且持续整个研究。
- 其他脂质和脂蛋白(载脂蛋白B、总胆固醇、非高密度脂蛋白胆固醇)水平组间无统计学显著差异。
关键数值与推荐
- 主要终点为基线至第150天LDL-C水平的百分比变化。
- 患者尽管接受最大耐受剂量降脂治疗(联合或不联合脂蛋白血浆置换),LDL-C水平仍升高。
临床怎么用
- 对于纯合子家族性高胆固醇血症患者,inclisiran虽能降低PCSK9水平,但未显示LDL-C降低获益。
- inclisiran在该人群中耐受性良好,安全性与其他研究一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homozygous familial hypercholesterolemia is a genetic disease characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature cardiovascular events. The proof-of-concept study ORION-2 (A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia) showed that inclisiran, a small interfering RNA that prevents production of the hepatic PCSK9 protein (proprotein convertase subtilisin/kexin type 9), could lead to durable reductions in LDL-C levels when added to statins and ezetimibe in patients with homozygous familial hypercholesterolemia. METHODS: ORION-5 was a phase 3, 2-part, multicenter study in 56 patients with homozygous familial hypercholesterolemia and elevated LDL-C levels despite maximum tolerated doses of LDL-C-lowering therapies with or without lipoprotein apheresis. Patients eligible for part 1 (double-blind, 6 months) were randomized 2:1 to receive either 300 mg of inclisiran sodium (equivalent to 284 mg of inclisiran) or placebo. Placebo-treated patients from part 1 were transitioned to inclisiran in part 2 (open-label, 18 months). The primary end point was the percentage change in LDL-C levels from baseline to day 150. RESULTS: The mean age of the patients was 42.7 years, and 60.7% were women. The mean baseline LDL-C levels were 294.0 mg/dL and 356.7 mg/dL in the inclisiran and placebo groups, respectively. The placebo-corrected percentage change in LDL-C level from baseline to day 150 was -1.68% (95% CI, -29.19% to 25.83%; P=0.90), and the difference was not statistically significant between the inclisiran and placebo groups. The placebo-corrected percentage change in PCSK9 levels from baseline to day 150 was -60.6% with inclisiran treatment (P<0.0001); this was sustained throughout the study, confirming the effect of inclisiran on its biological target of PCSK9. No statistically significant differences between the inclisiran and placebo groups were observed in the levels of other lipids and lipoproteins (apolipoprotein B, total cholesterol, and non-high-density lipoprotein cholesterol). Adverse events and serious adverse events did not differ between the inclisiran and placebo groups throughout the study. CONCLUSIONS: Inclisiran treatment did not reduce LDL-C levels in patients with homozygous familial hypercholesterolemia despite substantial lowering of PCSK9 levels. Inclisiran was well-tolerated, and the safety findings were consistent with previously reported studies and the overall safety profile. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03851705.
引用
- Raal F, Durst R, Bi R, et al. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2023. PMID: 37850379. doi:10.1161/CIRCULATIONAHA.122.063460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。